patientswww.38.com
www.38.com 时间:2021-03-21 阅读:()
WORLDJOURNALOFSURGICALONCOLOGYCheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38OpenAccessRESEARCHBioMedCentral2010Cheungetal;licenseeBioMedCentralLtd.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense(http://creativecommons.
org/licenses/by/2.
0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.
ResearchBonymetastasesfrombreastcancer-astudyoffoetalantigen2asabloodtumourmarkerKwok-LeungCheung*1,RayKIles2andJohnFRRobertson1AbstractBackground:Foetalantigen2(FA-2),firstisolatedintheamnioticfluid,wasshowntobethecirculatingformoftheaminopropeptideofthealpha1chainofprocollagentypeI.
SerumconcentrationsofFA-2appearedtobeelevatedinanumberofdisordersofbonemetabolism.
Thispaperisthefirstreportofitsroleasamarkerofbonemetabolisminmetastaticbreastcancer.
Methods:SerumFA-2concentrationsweremeasuredbyradioimmunoassayin153womenwithdifferentstagesofbreastcancerandin34normalcontrols.
Results:SerumFA-2wassignificantlyelevatedinwomenwithbonymetastases(p5cmand/orotherfeaturesoflocallyadvanceddisease(eginflammatorycancer,fixationtochestwall,ulceratingtumour)withoutanyevidenceofdistantmetastasesandattendedtheLAPCClinic.
Bloodsamplesweretakenwhenthetumourwasstillinsitu.
*Correspondence:kl.
cheung@nottingham.
ac.
uk1DivisionofBreastSurgery,UniversityofNottingham,Nottingham,UKFulllistofauthorinformationisavailableattheendofthearticleCheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page2of44.
Womenwithadvancedbreastcancer(ABC)-ThesewerewomenattendingtheABCClinicandallhaddistantmetastases.
PreparationofSerumSamplesBloodobtainedbyvenesectionwascollectedinplaintubes,allowedtostandforatleast30minutesandthencentrifugedat2,500revolutionsperminutefor20min-utes.
Serumwaspipettedinto1-mlaliquotsandstoredinthefreezerat-20°C.
FA-2AssaysTheserumsamplesweretransportedat-20°CtotheWil-liamsonLaboratoryatStBartholomew'sHospital.
FA-2radioimmunoassayswerecarriedoutaspreviouslydescribed[3].
Theassayswereperformedinablindman-nerwithaliquotstaggedwithasamplenumberwithoutanyclinicalinformation.
StatisticalMethodsStatisticalanalysiswascarriedoutusingthestandardisedbiomedicalcomputerprogrammeSPSSforWindows(SPSSUKLtd).
TheANOVAtestwasusedformultiplegroupcomparisonofthemeanvalues.
Statisticallysignif-icantdifferencewasdefinedbyp<0.
05.
TheauthorsconfirmthatapprovalhasbeenobtainedfromLocalResearchEthicsCommitteetoconductthisstudyonbloodmarkersinbreastcancer.
ResultsThemeanvaluesofserumFA-2levelsinallfourgroupsofwomenweresummarisedinTable1.
Therewasnodif-ferenceinFA-2levelsamongnormalwomenandwomenwithbreastcancerwhichwasstillconfinedtothebreast(iePBCandLAPC)(Tables1and2).
Nevertheless,whenallstagesofcancerweretakenintoconsideration,FA-2levelsappearedtobesignificantlyelevatedincancerpatientswhencomparedtonormalwomenandthiswasduetomarkedelevationinwomenwithmetastaticbreastcancer(Table2).
WomenwithmetastaticdiseasehadamuchhighervalueofFA-2thanthosewithout(Table3)andthiswasduetothesignificantelevationofFA-2inwomenwithbonymetastases(Figure1).
Inconclusion,theresultssuggestedthatFA-2wassig-nificantlyelevatedonlyinthesubgroupofwomenwithbonymetastases.
DiscussionBloodtumourmarkersinbreastcancerhavebeenknownfordecades.
Incontrasttomarkersintheprimarytumourtissue,bloodtumourmarkersreflectadynamicsituationandtheirmeasurementscanberepeatedasrequired.
Theuseofbloodtumourmarkersismostestab-lishedinthediagnosisandmonitoringofsymptomaticmetastaticdisease.
InthediagnosisofmetastaticbreastTable1:MeanValuesofFA-2forAllWomenSamplecategoryNMean±SD(AU/ml)Normal340.
21±0.
09PBC350.
18±0.
08LAPC380.
33±0.
67ABC800.
85±1.
34All187Figure1ComparisonofFA-2levelsbetweenboneandnon-bonemetastases.
SamplecategoryNMean±SD(AU/ml)pvalueNon-bonymetastasesBonymetastases*20530.
37±0.
360.
91±0.
940.
0149*Includingpatientswithbothskeletalandextra-skeletalmetastases.
non-boneboneMetastases0.
001.
002.
003.
004.
00AUperml$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$Cheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page3of4cancer,CA15.
3assayhasbeenshowntobesuperiorwithCEAbeingthenextmostclinicallyusefulmarker[4].
ThesensitivitycanbefurtherincreasedwhenapanelofthreemarkersieCA15.
3,CEAandESRareused[5-8].
Whiletheusefulnessofbloodtumourmarkersiswellestab-lishedinadvancedbreastcancer,activeresearch,bothclinicalandlaboratory,isongoingtorefinethemeasure-mentsofexistingmarkers,toexplorenewermarkersandtodevelopbettermarkerassays,aimingtooptimisetheiruseinadvanceddiseaseaswellastoexploittheiruseinscreeninganddiagnosisofearlyprimarybreastcancer.
Markersofbonemetabolismareamongthenewmark-erswhicharebeinginvestigated.
Traditionalmarkersofbonemetabolismincludeserumalkalinephosphatase,serumandurinarycalcium,urinaryhydroxprolineetc.
Markersofcollagensynthesishavebeenevaluatedasbonemarkersformetastaticbonediseaseduetobreastcancer.
ThemostabundantproteininboneistypeIcolla-gen.
Duringitsformationtwoextensionpeptidesfromtheprocollagenmolecule,carboxy-andaminoterminalpropeptides(PICPandPINP)arereleasedintothecircu-lationandtheyaremarkersofboneformation.
TypeIcol-lagencarboxyterminaltelopeptide(ICTP)isformedduringbonecollagenbreakdownandisagainliberatedintothecirculation.
Itslevelintheserumthereforereflectsboneresorption.
ICTPhasahighspecificitythoughrelativelylowsensitivityandisthebestbonemetabolismmarkerevaluated[9,10].
Furtherstudiestoevaluatethecost-effectivenessofmeasuringthesemark-ersandtoexplorenewermarkersofbonemetabolismarerequired[11].
Afteritsisolationfromtheamnioticfluid,FA-2wasfoundelevatedinserumofpatientswithrenalosteo-dystrophy[12]andwithprimaryhyperparathyroidism[13].
PatientswiththelatterhadFA-2levelsdroppedsig-nificantlyaftersurgicalremovaloftheparathyroidglands[13].
AllthesehavesuggestedFA-2asapossiblemarkertoevaluatebonemetabolism.
EvidenceofFA-2synthesisbyfoetalosteoblastsshownusingimmunohistochemicalstainingtechniqueshassubstantiatedthispotentialrole[14].
Thepresentstudyisthefirstreportofthemeasure-mentofserumFA-2indifferentstagesofbreastcancer.
ItshowedthatserumFA-2waselevateddistinctlyinwomenwithbonymetastases.
Itslevelsweresignificantlylowerinwomenwithoutmetastasesincludingnormalcontrols.
Thefactthatthemeanvalueinwomenwithmetastaseswassignificantlyhigherthatinwomenwith-outcouldentirelybeexplainedbytheinclusionofwomenwithbonymetastasesintheformergroup.
Themeanvalueinwomenwithnon-bonymetastaseswasvirtuallysimilartothatofthosewithoutmetastases.
InessenceserumFA-2hasbeenfoundtobesignificantlyelevatedonlyinthesubgroupofwomenwithbonymetastases.
ThesepreliminarydatapointoutthatFA-2isapotentialhelpfulbloodmarkerforbonymetastasesfrombreastcancer.
ItwouldthereforeappearthatserumFA-2mea-surementmaybeusefulinthediagnosisofbonymetasta-ses.
Whetheritwillbeshowntobesuperiortoexistingmarkersand/orradiologicalmethodsremainstobeeluci-dated.
Theotherroleoftumourmarkermeasurementisinthemonitoringoftherapy.
Inthepresenterawhentheuseofbisphosphonateshasbeenpopularisedinthemanage-mentofbonemetastasesforbreastcancer,markersofbonemetabolismmightprovideameasurementoftheeffectofsclerosisonthebonewhileconventionalbloodmarkerssuchasCA15.
3andCEAreflecttheefficacyofanti-cancertherapyontumourmass.
InthesewaysnewTable2:ComparisonofFA-2LevelsbetweenDifferentGroupsSamplecategorypvaluePBC0.
19LAPCSamplecategorypvaluePBC0.
0037ABCSamplecategorypvalueLAPC0.
0243ABCTable3:ComparisonofFA-2LevelsbetweenMetastaticandNon-MetastaticCancersSamplecategoryNMean±SD(AU/ml)pvalueNon-metastatic730.
26±0.
490.
0004Metastatic800.
85±1.
34Cheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page4of4markershaveacomplementaryratherthananexclusiveroleinthediagnosisandmonitoringofbreastcancer[11].
Giventhepreliminaryresultsfromthisobservationalstudywhichhasitsstatisticallimitationsduetoitssmallsize,furtherstudiesarethereforerequiredtodefineindetailstheexactvalueofserumFA-2measurementinbonymetastasesfrombreastcancer.
Comparisonwithconventionalmarkersoftumourmass(egCA15.
3,CEA)andknownnovelmarkersofbonemetabolism(egPICP,PINP,ICTP)(bothinthediagnosisandinthemonitoringofresponsetosystemictherapy),andidentificationofthepatternofchangesofserumFA-2levelsinrelationtobis-phosphonatetherapyandeventssuchashypercalcaemiaareareasthatneedtobeexploredbeforetheuseofFA-2couldbeincorporatedintodailyclinicalpractice.
AbbreviationsFA-2:Foetalantigen2;CA15.
3:Cancerantigen15.
3;CEA:Carcinoembryonicantigen;PBC:Primarybreastcancer;LAPC:Locallyadvancedprimarybreastcancer;ABC:Advancedbreastcancer;PICP:CarboxyterminalpropeptideoftypeIprocollagen;PINP:AminoterminalpropeptideoftypeIprocollagen;ICTP:TypeIcollagencarboxyterminaltelopeptide.
CompetinginterestsTheauthorsdeclarethattheyhavenocompetinginterests.
Authors'contributionsKLCperformedthestatisticalanalysisanddraftedthemanuscript.
AllpatientswereunderthecareofKLCandJFRRwhowereresponsibleforcollectingbloodsamplesandclinicaldata.
RKIwasresponsibleforcarryingouttheassayforFA-2.
JFRRconceivedofthestudy.
Allparticipatedinthedesign;readandapprovedthefinalmanuscript.
AuthorDetails1DivisionofBreastSurgery,UniversityofNottingham,Nottingham,UKand2WilliamsonLaboratory,StBartholomew'sHospital,London,UKReferences1.
FayTN,JacobsI,TeisnerB,PoulsenO,ChapmanMG,StabileI,BohnH,WestergaardJG,GrudzinskasJG:Twofetalantigens(FA-1andFA-2)andendometrialproteins(PP12andPP14)isolatedfromamnioticfluid;preliminaryobservationsinfetalandmaternaltissues.
EurJObstetGynecolReprodBiol1988,29:73-85.
2.
TeisnerB,RasmussenHB,HojrupP,Yde-AndersonE,SkjodtK:Fetalantigen2:anamnioticproteinidentifiedastheaminopropeptideofthealpha1chainofhumanprocollagentypeI.
APMIS1992,100:1106-14.
3.
PriceKM,SilmanR,ArmstrongP,GrudzinskasJG:Developmentofaradioimmunoassayforfetalantigen2.
ClinChimActa1994,224:95-102.
4.
KleistSV,BombardieriE,BuraggiG,GionM,HertelA,HrG,Noujaima,SchwartzM,SenekowitschR,WittekindC:Immunodiagnosisoftumours.
EurJCancer1993,29A:1622-30.
5.
RobertsonJFR,PearsonD,PriceMR,SelbyC,BlameyRW,HowellA:Objectivemeasurementoftherapeuticresponseinbreastcancerusingtumourmarkers.
BrJCancer1991,64:757-63.
6.
DixonAR:Tumourmarkers-alogicalapproachtotheguidanceoftherapyinadvancedbreastcancerInDoctorofMedicineThesisUniversityofNottingham;1991.
7.
DixonAR,JnrupI,JacksonL,ChanSY,BadleyRA,BlameyRW:SerologicalmonitoringofadvancedbreastcancertreatedbysystemiccytotoxicusingacombinationofESR,CEA,andCA15.
3:factorfictionDiseaseMarkers1991,9:167-74.
8.
DixonAR,JacksonL,ChanSY,BadleyRA,BlameyRW:Continuouschemotherapyinresponsivemetastaticbreastcancer:arolefortumourmarkersBrJCancer1993,68:181-5.
9.
PlebaniM,BernardiD,ZaninottoM,DePaoliM,SecchieroS,SciacovelliL:Newandtraditionalserummarkersofbonemetabolisminthedetectionofskeletalmetastases.
ClinBiochem1996,29:67-72.
10.
TahtelaR,TholixE:SerumconcentrationsoftypeIcollagencarboxyterminaltelopeptide(ICTP)andtypeIprocollagencarboxy-andaminoterminalpropeptides(PICP,PINP)asmarkersofmetastaticbonediseaseinbreastcancer.
AnticancerRes1996,16:2289-93.
11.
CheungKL,GravesCRL,RobertsonJFR:Tumourmarkermeasurementsinthediagnosisandmonitoringofbreastcancer.
CancerTreatRev2000,26:91-102.
12.
BojeRasmussenH,TeisnerB,Bangsgaard-PetersenF,Yde-AndersenE,KassemM:Quantificationoffetalantigen(FA-2)insupernatantsofculturedosteoblasts,normalhumanserum,andserumfrompatientswithchronicrenalfailure.
NephrolDialTransplant1992,7:902-7.
13.
BojeRasmussenH,TeisnerB,GramJ,BrixenK,Yde-AndersenE,BollerslevJ:Serumlevelsoffetalantigen2inhyperthyroidismandprimaryhyperparathyroidism.
APMIS1992,100:894-900.
14.
TornehaveD,TeisnerB,RasmussenHB,ChemnitzJ,KassemM:Fetalantigen2(FA-2)inhumanfetalosteoblasts,culturedosteoblastsandosteogenicosteosarcomacells.
AntEmbryol(Berl)1992,186:271-4.
doi:10.
1186/1477-7819-8-38Citethisarticleas:Cheungetal.
,Bonymetastasesfrombreastcancer-astudyoffoetalantigen2asabloodtumourmarkerWorldJournalofSurgicalOncology2010,8:38Received:16March2010Accepted:13May2010Published:13May2010Thisarticleisavailablefrom:http://www.
wjso.
com/content/8/1/382010Cheungetal;licenseeBioMedCentralLtd.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense(http://creativecommons.
org/licenses/by/2.
0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.
WorldJournalofSurgicalOncology2010,8:38
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38OpenAccessRESEARCHBioMedCentral2010Cheungetal;licenseeBioMedCentralLtd.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense(http://creativecommons.
org/licenses/by/2.
0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.
ResearchBonymetastasesfrombreastcancer-astudyoffoetalantigen2asabloodtumourmarkerKwok-LeungCheung*1,RayKIles2andJohnFRRobertson1AbstractBackground:Foetalantigen2(FA-2),firstisolatedintheamnioticfluid,wasshowntobethecirculatingformoftheaminopropeptideofthealpha1chainofprocollagentypeI.
SerumconcentrationsofFA-2appearedtobeelevatedinanumberofdisordersofbonemetabolism.
Thispaperisthefirstreportofitsroleasamarkerofbonemetabolisminmetastaticbreastcancer.
Methods:SerumFA-2concentrationsweremeasuredbyradioimmunoassayin153womenwithdifferentstagesofbreastcancerandin34normalcontrols.
Results:SerumFA-2wassignificantlyelevatedinwomenwithbonymetastases(p5cmand/orotherfeaturesoflocallyadvanceddisease(eginflammatorycancer,fixationtochestwall,ulceratingtumour)withoutanyevidenceofdistantmetastasesandattendedtheLAPCClinic.
Bloodsamplesweretakenwhenthetumourwasstillinsitu.
*Correspondence:kl.
cheung@nottingham.
ac.
uk1DivisionofBreastSurgery,UniversityofNottingham,Nottingham,UKFulllistofauthorinformationisavailableattheendofthearticleCheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page2of44.
Womenwithadvancedbreastcancer(ABC)-ThesewerewomenattendingtheABCClinicandallhaddistantmetastases.
PreparationofSerumSamplesBloodobtainedbyvenesectionwascollectedinplaintubes,allowedtostandforatleast30minutesandthencentrifugedat2,500revolutionsperminutefor20min-utes.
Serumwaspipettedinto1-mlaliquotsandstoredinthefreezerat-20°C.
FA-2AssaysTheserumsamplesweretransportedat-20°CtotheWil-liamsonLaboratoryatStBartholomew'sHospital.
FA-2radioimmunoassayswerecarriedoutaspreviouslydescribed[3].
Theassayswereperformedinablindman-nerwithaliquotstaggedwithasamplenumberwithoutanyclinicalinformation.
StatisticalMethodsStatisticalanalysiswascarriedoutusingthestandardisedbiomedicalcomputerprogrammeSPSSforWindows(SPSSUKLtd).
TheANOVAtestwasusedformultiplegroupcomparisonofthemeanvalues.
Statisticallysignif-icantdifferencewasdefinedbyp<0.
05.
TheauthorsconfirmthatapprovalhasbeenobtainedfromLocalResearchEthicsCommitteetoconductthisstudyonbloodmarkersinbreastcancer.
ResultsThemeanvaluesofserumFA-2levelsinallfourgroupsofwomenweresummarisedinTable1.
Therewasnodif-ferenceinFA-2levelsamongnormalwomenandwomenwithbreastcancerwhichwasstillconfinedtothebreast(iePBCandLAPC)(Tables1and2).
Nevertheless,whenallstagesofcancerweretakenintoconsideration,FA-2levelsappearedtobesignificantlyelevatedincancerpatientswhencomparedtonormalwomenandthiswasduetomarkedelevationinwomenwithmetastaticbreastcancer(Table2).
WomenwithmetastaticdiseasehadamuchhighervalueofFA-2thanthosewithout(Table3)andthiswasduetothesignificantelevationofFA-2inwomenwithbonymetastases(Figure1).
Inconclusion,theresultssuggestedthatFA-2wassig-nificantlyelevatedonlyinthesubgroupofwomenwithbonymetastases.
DiscussionBloodtumourmarkersinbreastcancerhavebeenknownfordecades.
Incontrasttomarkersintheprimarytumourtissue,bloodtumourmarkersreflectadynamicsituationandtheirmeasurementscanberepeatedasrequired.
Theuseofbloodtumourmarkersismostestab-lishedinthediagnosisandmonitoringofsymptomaticmetastaticdisease.
InthediagnosisofmetastaticbreastTable1:MeanValuesofFA-2forAllWomenSamplecategoryNMean±SD(AU/ml)Normal340.
21±0.
09PBC350.
18±0.
08LAPC380.
33±0.
67ABC800.
85±1.
34All187Figure1ComparisonofFA-2levelsbetweenboneandnon-bonemetastases.
SamplecategoryNMean±SD(AU/ml)pvalueNon-bonymetastasesBonymetastases*20530.
37±0.
360.
91±0.
940.
0149*Includingpatientswithbothskeletalandextra-skeletalmetastases.
non-boneboneMetastases0.
001.
002.
003.
004.
00AUperml$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$Cheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page3of4cancer,CA15.
3assayhasbeenshowntobesuperiorwithCEAbeingthenextmostclinicallyusefulmarker[4].
ThesensitivitycanbefurtherincreasedwhenapanelofthreemarkersieCA15.
3,CEAandESRareused[5-8].
Whiletheusefulnessofbloodtumourmarkersiswellestab-lishedinadvancedbreastcancer,activeresearch,bothclinicalandlaboratory,isongoingtorefinethemeasure-mentsofexistingmarkers,toexplorenewermarkersandtodevelopbettermarkerassays,aimingtooptimisetheiruseinadvanceddiseaseaswellastoexploittheiruseinscreeninganddiagnosisofearlyprimarybreastcancer.
Markersofbonemetabolismareamongthenewmark-erswhicharebeinginvestigated.
Traditionalmarkersofbonemetabolismincludeserumalkalinephosphatase,serumandurinarycalcium,urinaryhydroxprolineetc.
Markersofcollagensynthesishavebeenevaluatedasbonemarkersformetastaticbonediseaseduetobreastcancer.
ThemostabundantproteininboneistypeIcolla-gen.
Duringitsformationtwoextensionpeptidesfromtheprocollagenmolecule,carboxy-andaminoterminalpropeptides(PICPandPINP)arereleasedintothecircu-lationandtheyaremarkersofboneformation.
TypeIcol-lagencarboxyterminaltelopeptide(ICTP)isformedduringbonecollagenbreakdownandisagainliberatedintothecirculation.
Itslevelintheserumthereforereflectsboneresorption.
ICTPhasahighspecificitythoughrelativelylowsensitivityandisthebestbonemetabolismmarkerevaluated[9,10].
Furtherstudiestoevaluatethecost-effectivenessofmeasuringthesemark-ersandtoexplorenewermarkersofbonemetabolismarerequired[11].
Afteritsisolationfromtheamnioticfluid,FA-2wasfoundelevatedinserumofpatientswithrenalosteo-dystrophy[12]andwithprimaryhyperparathyroidism[13].
PatientswiththelatterhadFA-2levelsdroppedsig-nificantlyaftersurgicalremovaloftheparathyroidglands[13].
AllthesehavesuggestedFA-2asapossiblemarkertoevaluatebonemetabolism.
EvidenceofFA-2synthesisbyfoetalosteoblastsshownusingimmunohistochemicalstainingtechniqueshassubstantiatedthispotentialrole[14].
Thepresentstudyisthefirstreportofthemeasure-mentofserumFA-2indifferentstagesofbreastcancer.
ItshowedthatserumFA-2waselevateddistinctlyinwomenwithbonymetastases.
Itslevelsweresignificantlylowerinwomenwithoutmetastasesincludingnormalcontrols.
Thefactthatthemeanvalueinwomenwithmetastaseswassignificantlyhigherthatinwomenwith-outcouldentirelybeexplainedbytheinclusionofwomenwithbonymetastasesintheformergroup.
Themeanvalueinwomenwithnon-bonymetastaseswasvirtuallysimilartothatofthosewithoutmetastases.
InessenceserumFA-2hasbeenfoundtobesignificantlyelevatedonlyinthesubgroupofwomenwithbonymetastases.
ThesepreliminarydatapointoutthatFA-2isapotentialhelpfulbloodmarkerforbonymetastasesfrombreastcancer.
ItwouldthereforeappearthatserumFA-2mea-surementmaybeusefulinthediagnosisofbonymetasta-ses.
Whetheritwillbeshowntobesuperiortoexistingmarkersand/orradiologicalmethodsremainstobeeluci-dated.
Theotherroleoftumourmarkermeasurementisinthemonitoringoftherapy.
Inthepresenterawhentheuseofbisphosphonateshasbeenpopularisedinthemanage-mentofbonemetastasesforbreastcancer,markersofbonemetabolismmightprovideameasurementoftheeffectofsclerosisonthebonewhileconventionalbloodmarkerssuchasCA15.
3andCEAreflecttheefficacyofanti-cancertherapyontumourmass.
InthesewaysnewTable2:ComparisonofFA-2LevelsbetweenDifferentGroupsSamplecategorypvaluePBC0.
19LAPCSamplecategorypvaluePBC0.
0037ABCSamplecategorypvalueLAPC0.
0243ABCTable3:ComparisonofFA-2LevelsbetweenMetastaticandNon-MetastaticCancersSamplecategoryNMean±SD(AU/ml)pvalueNon-metastatic730.
26±0.
490.
0004Metastatic800.
85±1.
34Cheungetal.
WorldJournalofSurgicalOncology2010,8:38http://www.
wjso.
com/content/8/1/38Page4of4markershaveacomplementaryratherthananexclusiveroleinthediagnosisandmonitoringofbreastcancer[11].
Giventhepreliminaryresultsfromthisobservationalstudywhichhasitsstatisticallimitationsduetoitssmallsize,furtherstudiesarethereforerequiredtodefineindetailstheexactvalueofserumFA-2measurementinbonymetastasesfrombreastcancer.
Comparisonwithconventionalmarkersoftumourmass(egCA15.
3,CEA)andknownnovelmarkersofbonemetabolism(egPICP,PINP,ICTP)(bothinthediagnosisandinthemonitoringofresponsetosystemictherapy),andidentificationofthepatternofchangesofserumFA-2levelsinrelationtobis-phosphonatetherapyandeventssuchashypercalcaemiaareareasthatneedtobeexploredbeforetheuseofFA-2couldbeincorporatedintodailyclinicalpractice.
AbbreviationsFA-2:Foetalantigen2;CA15.
3:Cancerantigen15.
3;CEA:Carcinoembryonicantigen;PBC:Primarybreastcancer;LAPC:Locallyadvancedprimarybreastcancer;ABC:Advancedbreastcancer;PICP:CarboxyterminalpropeptideoftypeIprocollagen;PINP:AminoterminalpropeptideoftypeIprocollagen;ICTP:TypeIcollagencarboxyterminaltelopeptide.
CompetinginterestsTheauthorsdeclarethattheyhavenocompetinginterests.
Authors'contributionsKLCperformedthestatisticalanalysisanddraftedthemanuscript.
AllpatientswereunderthecareofKLCandJFRRwhowereresponsibleforcollectingbloodsamplesandclinicaldata.
RKIwasresponsibleforcarryingouttheassayforFA-2.
JFRRconceivedofthestudy.
Allparticipatedinthedesign;readandapprovedthefinalmanuscript.
AuthorDetails1DivisionofBreastSurgery,UniversityofNottingham,Nottingham,UKand2WilliamsonLaboratory,StBartholomew'sHospital,London,UKReferences1.
FayTN,JacobsI,TeisnerB,PoulsenO,ChapmanMG,StabileI,BohnH,WestergaardJG,GrudzinskasJG:Twofetalantigens(FA-1andFA-2)andendometrialproteins(PP12andPP14)isolatedfromamnioticfluid;preliminaryobservationsinfetalandmaternaltissues.
EurJObstetGynecolReprodBiol1988,29:73-85.
2.
TeisnerB,RasmussenHB,HojrupP,Yde-AndersonE,SkjodtK:Fetalantigen2:anamnioticproteinidentifiedastheaminopropeptideofthealpha1chainofhumanprocollagentypeI.
APMIS1992,100:1106-14.
3.
PriceKM,SilmanR,ArmstrongP,GrudzinskasJG:Developmentofaradioimmunoassayforfetalantigen2.
ClinChimActa1994,224:95-102.
4.
KleistSV,BombardieriE,BuraggiG,GionM,HertelA,HrG,Noujaima,SchwartzM,SenekowitschR,WittekindC:Immunodiagnosisoftumours.
EurJCancer1993,29A:1622-30.
5.
RobertsonJFR,PearsonD,PriceMR,SelbyC,BlameyRW,HowellA:Objectivemeasurementoftherapeuticresponseinbreastcancerusingtumourmarkers.
BrJCancer1991,64:757-63.
6.
DixonAR:Tumourmarkers-alogicalapproachtotheguidanceoftherapyinadvancedbreastcancerInDoctorofMedicineThesisUniversityofNottingham;1991.
7.
DixonAR,JnrupI,JacksonL,ChanSY,BadleyRA,BlameyRW:SerologicalmonitoringofadvancedbreastcancertreatedbysystemiccytotoxicusingacombinationofESR,CEA,andCA15.
3:factorfictionDiseaseMarkers1991,9:167-74.
8.
DixonAR,JacksonL,ChanSY,BadleyRA,BlameyRW:Continuouschemotherapyinresponsivemetastaticbreastcancer:arolefortumourmarkersBrJCancer1993,68:181-5.
9.
PlebaniM,BernardiD,ZaninottoM,DePaoliM,SecchieroS,SciacovelliL:Newandtraditionalserummarkersofbonemetabolisminthedetectionofskeletalmetastases.
ClinBiochem1996,29:67-72.
10.
TahtelaR,TholixE:SerumconcentrationsoftypeIcollagencarboxyterminaltelopeptide(ICTP)andtypeIprocollagencarboxy-andaminoterminalpropeptides(PICP,PINP)asmarkersofmetastaticbonediseaseinbreastcancer.
AnticancerRes1996,16:2289-93.
11.
CheungKL,GravesCRL,RobertsonJFR:Tumourmarkermeasurementsinthediagnosisandmonitoringofbreastcancer.
CancerTreatRev2000,26:91-102.
12.
BojeRasmussenH,TeisnerB,Bangsgaard-PetersenF,Yde-AndersenE,KassemM:Quantificationoffetalantigen(FA-2)insupernatantsofculturedosteoblasts,normalhumanserum,andserumfrompatientswithchronicrenalfailure.
NephrolDialTransplant1992,7:902-7.
13.
BojeRasmussenH,TeisnerB,GramJ,BrixenK,Yde-AndersenE,BollerslevJ:Serumlevelsoffetalantigen2inhyperthyroidismandprimaryhyperparathyroidism.
APMIS1992,100:894-900.
14.
TornehaveD,TeisnerB,RasmussenHB,ChemnitzJ,KassemM:Fetalantigen2(FA-2)inhumanfetalosteoblasts,culturedosteoblastsandosteogenicosteosarcomacells.
AntEmbryol(Berl)1992,186:271-4.
doi:10.
1186/1477-7819-8-38Citethisarticleas:Cheungetal.
,Bonymetastasesfrombreastcancer-astudyoffoetalantigen2asabloodtumourmarkerWorldJournalofSurgicalOncology2010,8:38Received:16March2010Accepted:13May2010Published:13May2010Thisarticleisavailablefrom:http://www.
wjso.
com/content/8/1/382010Cheungetal;licenseeBioMedCentralLtd.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense(http://creativecommons.
org/licenses/by/2.
0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.
WorldJournalofSurgicalOncology2010,8:38
- patientswww.38.com相关文档
- 景顺长城景瑞睿利回报定期开放混合型证券投资基金关于
- 详见www.38.com
- "洛杉矶中资企业协会会员名册ChineseEnterpriseCouncil",,,,
- 非洲www.38.com
- carcinogenicwww.38.com
- physicianwww.38.com
快云科技：香港沙田CN2云服务器低至29元/月起;美国高防弹性云/洛杉矶CUVIP低至33.6元/月起
快云科技怎么样?快云科技是一家成立于2020年的新起国内主机商，资质齐全 持有IDC ICP ISP等正规商家。云服务器网(yuntue.com)小编之前已经介绍过很多快云科技的香港及美国云服务器了，这次再介绍一下新的优惠方案。目前，香港云沙田CN2云服务器低至29元/月起;美国超防弹性云/洛杉矶CUVIP低至33.6元/月起。快云科技的云主机架构采用KVM虚拟化技术，全盘SSD硬盘，RAID10...
腾讯云新用户省钱秘笈购买云服务器
目前国内云计算市场竞争异常激烈，尤其是国内的腾讯云、阿里云、景安等商家促销活动一波接一波的进行，对于有需要的用户确实得到不小的实惠。但是这样给予国内的主机商确实是比较大的打击，毕竟这些商家的背景和实例强劲，即便是贴本补贴优惠，也是不怕的。前两年阿里一家各种活动促销，确实在国内市场占据主要的市场地位，腾讯云开始两年没有较大的吸引用户，不过这两年的发展还是比较稳健的。我们很多网友在之前肯定也享受到一些...
Contabo美国独立日促销,独立服7月€3.99/月
Contabo自4月份在新加坡增设数据中心以后，这才短短的过去不到3个月，现在同时新增了美国纽约和西雅图数据中心。可见Contabo加速了全球布局，目前可选的数据中心包括：德国本土、美国东部（纽约）、美国西部（西雅图）、美国中部（圣路易斯）和亚洲的新加坡数据中心。为了庆祝美国独立日和新增数据中心，自7月4日开始，购买美国地区的VPS、VDS和独立服务器均免设置费。Contabo是德国的老牌服务商，...
www.38.com为你推荐
-
公司网络被攻击最近企业受到网络攻击的事件特别多，怎么才能有效地保护企业的网络安全呢？阿丽克丝·布莱肯瑞吉阿丽克斯布莱肯瑞吉演的美国恐怖故事哪两集广东GDP破10万亿想知道广东城市的GDP排名haole018.comse.haole004.com为什么手机不能放？8090lu.com8090lu.com怎么样了?工程有进展吗？ip在线查询我要用eclipse做个ip在线查询功能，用QQwry数据库，可是我不知道怎么把这个数据库放到我的程序里面去，高手帮忙指点下，小弟在这谢谢了33tutu.com33gan.com改成什么了sodu.tw给个看免费小说的网站彪言彪语寻找一个电影和里面的一首歌，国产的，根据真实故事改编的校园爱情电影，里面的男主角是个屌丝但很会弹钢国风商讯国风轮胎待遇怎么样